Journal of Drugs in Dermatology最新文献

Background: Energy-based devices (EBDs) are increasingly used to manage acne and its sequelae. While literature supports the use of appropriate skin care for acne, few studies address how to effectively integrate skincare with EBDs.

Methods: Six dermatologists from North America, participated in a live meeting to develop an acne treatment algorithm integrating skincare and EBDs. Six additional advisors contributed through a pre-meeting survey (along with 94 other physicians). The eleven dermatologists (authors) from Asia, Europe, Australia, and North America participated in algorithm development and manuscript review.

Results: The proposed algorithm describes how to integrate skin care with the use of EBDs in clinical practice.

Conclusions: This algorithm provides an approach for managing acne and best practices for integrating skin care with EBDs when treating acne and acne sequelae.  .

Background: Oral lichen planus (OLP) patients with erythematous or erosive gingival lesions frequently fail topical therapy. The aim of this study was to determine the efficacy of minocycline and doxycycline for inflammatory and refractory gingival OLP.

Methods: In this retrospective analysis, the data of 254 patients with biopsy-confirmed OLP who displayed inflammatory gingival lesions and failed treatment with topical agents were analyzed. Patients treated between 2015 and 2023 with a 2-month course of either doxycycline 100 mg twice daily or minocycline 100 mg twice daily, concomitantly with topical agents, were included.

Results: After 2 months of treatment with doxycycline or minocycline, 60.6% patients improved with a marked reduction in erythema (95% CI 54.6%-66.6%). More specifically, in patients with mild gingival inflammation at baseline, 80.3% improved (95% CI 71.3%-89.2%) compared to 29.4% of patients with desquamative gingivitis at baseline (95% CI 16.9%-41.9%). Acute flare-ups after discontinuing therapy, which developed in approximately 25% of patients, responded to additional courses of antibiotics for 1to 2 months. Mild adverse effects were noted in 10 patients, which all resolved rapidly when the drug was discontinued.

Conclusions: This study demonstrates that both doxycycline and minocycline are highly effective agents for inflammatory gingival OLP lesions that are difficult to palliate. As these patients often fail to respond to topical agents and require more aggressive systemic drugs that are immunosuppressive with significant adverse effects, second-generation tetracyclines should be considered first-line systemic agents for inflammatory gingival OLP lesions.

Periorbital hyperpigmentation is a common yet challenging cosmetic concern due to the thin, vascular, and pigment-prone nature of periocular skin, as well as its multifactorial etiology. Discoloration in this area can be driven by genetics, photoaging, dermal thinning, and pigmentary disorders, making treatment outcomes often unpredictable and temporary. The cysteamine–isobionic amide complex offers a novel, non-hydroquinone and non-retinoid approach, combining the multi-pathway pigment reduction of cysteamine with the barrier-supporting and pigment-evening properties of isobionic amide. This pilot study aimed to evaluate the safety, tolerability, and efficacy of the cysteamine-isobionic amide complex for periorbital hyperpigmentation using objective imaging and patient-reported outcomes. Seven participants self-administered treatment three to five times weekly for 10 weeks. Patient-reported outcomes demonstrated consistent improvements in pigmentation, radiance, and overall appearance, with 83.3% noting improvement in their primary concern and 100% indicating they would recommend the regimen. The treatment was well tolerated, with only one case of transient mild erythema. To our knowledge, this is one of the first studies to investigate the cysteamine–isobionic amide complex in the periorbital region, supporting its potential as a safe, at-home option for under-eye hyperpigmentation. Future controlled trials with larger and more diverse cohorts are warranted to confirm these preliminary findings and assess long-term efficacy.  .